Key result
This review summarizes the epidemiology, pathogenesis, clinical characteristics, and current knowledge on the use of vasodilator therapy in patients with HIV-associated pulmonary arterial hypertension.
Why the study?
Pulmonary arterial hypertension is an important noninfectious complication in people living with human immunodeficiency virus.
This review summarizes the epidemiology, pathogenesis, clinical characteristics, and use of vasodilator therapy for HIV-associated pulmonary arterial hypertension.
Human immunodeficiency virus (HIV) attacks the immune system and can cause acquired immunodeficiency syndrome. Thankfully, antiretroviral therapy is highly effective, and people infected with HIV can live long lives with proper adherence to therapy. One of the important noninfectious complications of HIV is the development of pulmonary arterial hypertension (PAH). This review will cover the epidemiology, pathogenesis, and clinical characteristics of HIV-associated PAH. It will also cover the current knowledge on use of vasodilator therapy in this population.
No takes yet. Share an insight, caveat, or question.
Kolaitis et al. (2022) conducted a review in Human Immunodeficiency Virus-Associated Pulmonary Arterial Hypertension. Vasodilator therapy was evaluated. This review summarizes the epidemiology, pathogenesis, clinical characteristics, and current knowledge on the use of vasodilator therapy in patients with HIV-associated pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: